Profile data is unavailable for this security.
About the company
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its Anti-diabetic products include Gliclazide 80 mg, Tablets, Gliclazide 30 mg, Tablets, Glimepiride 1, 2, 3, 4 mg, Tablets, and others. Its dermatologic therapy products include Macrotor, Ahaglow S Facewash, Fungicide Lotion, Hairjoy 2%, New Dewsoft Cream, Lookbrite 20GMS, Cortaz NC, Dermanex, and others. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.
- Revenue in INR (TTM)109.96bn
- Net income in INR17.35bn
- Incorporated1972
- Employees14.92k
- LocationTorrent Pharmaceuticals LtdTorrent House, Off. Ashram RoadAHMEDABAD 380009IndiaIND
- Phone+91 7 926599000
- Fax+91 7 926582100
- Websitehttps://www.torrentpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott India Ltd | 59.28bn | 12.39bn | 599.40bn | 3.81k | 48.38 | -- | 45.71 | 10.11 | 583.08 | 583.08 | 2,789.54 | -- | -- | -- | -- | 15,541,480.00 | -- | 20.92 | -- | 28.59 | 45.28 | 44.20 | 20.90 | 17.26 | -- | 119.46 | -- | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Alkem Laboratories Ltd | 127.32bn | 20.54bn | 727.76bn | 17.28k | 35.43 | -- | 30.56 | 5.72 | 171.81 | 171.81 | 1,064.87 | -- | -- | -- | -- | 7,369,150.00 | -- | 11.88 | -- | 17.50 | 62.21 | 59.26 | 16.29 | 13.94 | -- | 9.12 | -- | 29.82 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 297.18bn | 35.21bn | 869.08bn | 8.80k | 24.89 | -- | 17.08 | 2.92 | 60.12 | 60.12 | 507.19 | -- | -- | -- | -- | 33,782,390.00 | -- | 9.24 | -- | 13.43 | 57.87 | 53.30 | 11.84 | 12.72 | -- | 13.17 | -- | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Lupin Ltd | 207.97bn | 22.64bn | 981.47bn | 20.79k | 43.46 | -- | 29.77 | 4.72 | 49.50 | 49.50 | 454.84 | -- | -- | -- | -- | 10,003,890.00 | -- | 1.43 | -- | 2.22 | 67.58 | 58.52 | 11.00 | 2.04 | -- | 9.67 | -- | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Mankind Pharma Ltd | 106.50bn | 19.63bn | 1.02tn | 19.54k | 51.84 | -- | 42.17 | 9.54 | 48.91 | 48.91 | 265.43 | -- | -- | -- | -- | 5,450,142.00 | -- | -- | -- | -- | 69.93 | -- | 18.69 | -- | -- | -- | -- | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Zydus Lifesciences Ltd | 206.15bn | 41.69bn | 1.06tn | 26.24k | 25.55 | -- | 21.30 | 5.15 | 41.28 | 41.51 | 204.01 | -- | -- | -- | -- | 7,856,441.00 | -- | 9.05 | -- | 14.01 | 70.22 | 61.15 | 20.29 | 14.33 | -- | -- | -- | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Dr Reddy's Laboratories Ltd | 289.49bn | 55.65bn | 1.09tn | 26.34k | 19.63 | -- | 15.45 | 3.77 | 333.72 | 333.72 | 1,735.89 | -- | -- | -- | -- | 10,989,370.00 | -- | 11.37 | -- | 16.02 | 70.80 | 65.86 | 19.22 | 14.63 | -- | 36.60 | -- | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Torrent Pharmaceuticals Ltd | 109.96bn | 17.35bn | 1.17tn | 14.92k | 67.44 | -- | 46.13 | 10.64 | 51.27 | 51.27 | 324.85 | -- | -- | -- | -- | 7,371,843.00 | -- | 8.34 | -- | 13.03 | 75.17 | 71.78 | 15.78 | 13.18 | -- | 8.19 | -- | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Cipla Ltd | 261.39bn | 43.03bn | 1.32tn | 27.76k | 30.76 | -- | 24.54 | 5.06 | 53.27 | 53.27 | 323.59 | -- | -- | -- | -- | 9,414,760.00 | -- | 10.09 | -- | 12.40 | 66.43 | 58.63 | 16.58 | 12.66 | -- | 59.65 | -- | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Divi's Laboratories Ltd | 81.85bn | 16.74bn | 1.45tn | 17.50k | 86.45 | -- | 70.38 | 17.68 | 63.05 | 63.05 | 308.33 | -- | -- | -- | -- | 4,677,143.00 | -- | 16.55 | -- | 18.22 | 59.76 | 56.24 | 20.45 | 26.38 | -- | -- | -- | 34.32 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Sep 2024 | 3.64m | 1.08% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 3.39m | 1.00% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.63m | 0.78% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Aug 2024 | 2.42m | 0.72% |
| ICICI Prudential Life Insurance Co. Ltd. (Invt Port)as of 31 Aug 2024 | 2.11m | 0.62% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Aug 2024 | 1.99m | 0.59% |
| Goldman Sachs Asset Management LPas of 12 Sep 2024 | 1.89m | 0.56% |
| Templeton Asset Management Ltd.as of 30 Jun 2024 | 1.64m | 0.49% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Aug 2024 | 1.48m | 0.44% |
| Fidelity Management & Research Co. LLCas of 31 Jul 2024 | 1.46m | 0.43% |
